SEHK:9995Biotechs
Does RemeGen’s Narrowed Net Loss and Rising Revenue Shift Sentiment on SEHK:9995’s Recovery Potential?
RemeGen Co., Ltd. reported earnings for the nine months ended September 30, 2025, with sales and revenue rising to CNY 1,719.83 million from CNY 1,208.87 million a year earlier, while its net loss narrowed to CNY 550.7 million from CNY 1,071.43 million.
The company also reported that its basic and diluted loss per share from continuing operations dropped to CNY 1.01 from CNY 1.99 in the previous year.
We'll explore how RemeGen’s reduced net loss and improved revenue shape its investment...